Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;52(7):2629-32.
doi: 10.1128/JCM.00656-14. Epub 2014 Apr 23.

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent

James E Ross  1 , Nicole E Scangarella-Oman  2 , Robert K Flamm  3 , Ronald N Jones  4
Affiliations

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent

James E Ross et al. J Clin Microbiol. 2014 Jul.

Abstract

GSK2140944 is a novel bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and methicillin-resistant Staphylococcus aureus. This quality control study was performed to establish ranges for selected control strains: S. aureus ATCC 29213 and ATCC 25923, Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247, and Streptococcus pneumoniae ATCC 49619. The control ranges will be crucial for the accurate evaluation of GSK2140944 potency as it progresses through clinical trial development.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Chemical structure of GSK2140944.
FIG 2
FIG 2
CLSI-approved GSK2140944 MIC quality control ranges for S. aureus ATCC 29213 (A), E. coli ATCC 25922 (B), H. influenzae ATCC 49247 (C), and S. pneumoniae ATCC 49619 (D).
FIG 3
FIG 3
CLSI-approved GSK2140944 disk diffusion quality control zone diameter ranges for E. coli ATCC 25922 (A), S. aureus ATCC 25923 (B), and S. pneumoniae ATCC 49619 (excluding laboratory C) (C).
See this image and copyright information in PMC

References

    1. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940. 10.1038/nature09197 - DOI - PubMed
    1. Bouchillon S, Hackel M, Miller LA, Scangarella-Oman NE. 2013. In vitro activity of GSK2140944, a novel topoisomerase inhibitor, against isolates associated with lower respiratory tract and skin infections, abstr F-1216 Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., Denver, CO, 10 to 13 September, 2013
    1. Clinical and Laboratory Standards Institute. 2008. M23–A3. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 3rd ed. CLSI document M23–A3. Clinical and Laboratory Standards Institute, Wayne, PA
    1. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial disk susceptibility tests; approved standard—11th ed CLSI document M02-A11. Clinical and Laboratory Standards Institute, Wayne, PA
    1. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA

Publication types

MeSH terms

Substances

LinkOut - more resources